 6 Century Drive, 2nd Floor  
Parsippany, NJ 07054 
 
 
 
 
Clinical Study Protocol  
CCP-020 (Diacerein 1%) Topical Ointment 
Sponsor Protocol No. CCP-020 -103 
TKL Study No. DS 106217 
 
 
A Randomized, Controlled Study to Evaluate the Sensitizing 
Potential of CCP- 020 (Diacerein 1%) Topical Ointment  in Healthy 
Subjects Using a Repeat Insult Patch Test Design  
 
 
Author:      
Document type:    Clinical Study Protocol  
Development Phase:    1 
Document Date:    23- October -2017 
Document Status   Amendment 1 
Number of Pages:    41 
 
 
 
Property of Castle Creek Pharmaceuticals, LLC  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of Castle Creek Pharmaceuticals, LLC  
 
 
  

Castle Creek Pharmaceuticals, L LC Confidential   Page 2 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  Synopsis  
Study Title:  A Randomized, Controlled Study to Evaluate the Sensitizing Potential of 
CCP -020 (Diacerein 1%) Topical Ointment  in Healthy Subjects Using a 
Repeat Insult Patch Test Design  
TKL Study  Number:  DS106217  
Sponsor Protocol Number:  CCP -020-103 
Sponsor:  Castle Creek Pharmaceuticals, LLC  
Development Phase:  1 
Study Objectives:  To evaluat e the sensitization  potential of CCP -020 (Diacerein 1%) Topical 
Ointment  on normal skin.   
Study Design:  Single center, randomized, controlled, evaluator blinded, within -subject 
comparison study . 
Planned Sample Size:  200 evaluable subjects  
Study  Popula tion:  Healthy adult males and  female s volunteer subjects  
Investigational Products : CCP -020 (Diacerein 1%) Topical Ointment , approximately 0.2 mL, applied  
topically under occlusive patch conditions to the i nfrascapular area of the 
back, 3 times weekly for 3 weeks (9 applications) during the Induction Phase, 
and one time at Challenge (10 times in total).  
Vehicle , approximately 0.2 mL, applied topically  under occlusive patch 
condition s to the infrascapular area of the back, 3 times weekly for 3 weeks 
(9 appli cations) during the Induction Phase, and one time at Challenge (10 
times in total).  
Concurrent Controls : A solution of 0.9% saline, approximately 0.2 mL  applied topically under 
occlusive patch conditions  to the infrascapular area of the back , 3 times 
week ly for 3 weeks (9 applications) during the Induction Phase, and one time 
at Challenge (10 times in total) will serve as a negative irritant control.  
Efficacy Evaluation Criteria : Not Applicable  
Safety Evaluation Criteria : All local and systemic adverse events (AEs) observed by or reported to the 
Investigator throughout the study will be evaluated.  The intensity, duration , 
and causal relationship to the investigational patch  are to be rated for all AEs . 
Statistical Methods : Cumulative irritancy during In duction will be quantified using the mean and 
total cumulative irritancy scores received during the Induction Phase (9 
readings). This parameter will be tested pairwise for product differences 
using analysis of variance (subject, product).  
A narrative des cription of reactions in the Challenge and Rechallenge Phases 
will be provided together with the opinion of the Investigator as to whether 
such reactions are felt to be indicative of contact sensitization.  
Number of Study Centers : Single center  
 
  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 5 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  Investigators and study administrative structure  
   
 
  
  
 
  
 
 
  
  
  
  
 
 
  
   
 
  
 
 
  
  
  
  
 
 
  
  
 
   
                                       
 
  
  
   
 
  
                                       
 
  
  
  
  
 
   
                                       
 
  
  
  
  
 
     
                                       
 
  
 
    

Castle Creek Pharmaceuticals, L LC Confidential   Page 6 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  TAB LE OF CONTENTS 
Signature page  ..................................................................................................................................3  
Signature page for the Principal Investigator ...................................................................................4  
Investigators and study administrative structure ..............................................................................5  
List of Abbreviations  .......................................................................................................................9  
1. INTRODUCTION  ......................................................................................................10  
1.1. Background Information .............................................................................................10  
1.2. Rationale for the Study  ...............................................................................................11  
2. STUDY OBJECTIVES  ..............................................................................................12  
3. INVESTIGATIONAL PLAN  .....................................................................................13  
3.1. Study Design  ...............................................................................................................13  
3.2. Discussion of De sign ..................................................................................................13  
3.3. Study Population  .........................................................................................................14  
3.3.1.  Subject Population  ......................................................................................................14  
3.3.2.  Inclusion and Exclusion Criteria  ................................................................................14  
3.3.3.  Interruption or Discontinuation of Treatment  .............................................................15  
3.3.4.  Withdrawals  ................................................................................................................16  
3.4. Treatments  ..................................................................................................................17  
3.4.1.  Investigational Product and Controls ..........................................................................17  
3.4.2.  Description of Investigational Products  ......................................................................18  
3.4.3.  Description of Patch Conditions  .................................................................................18  
3.4.4.  Packaging/Labeling  ....................................................................................................18  
3.4.5.  Assignment to Treatment  ............................................................................................19  
3.4.5.1.  Randomization  ............................................................................................................19  
3.4.5.2.  Blinding ......................................................................................................................19  
3.4.6.  Prior and Concomitant Therapy  ..................................................................................19  
3.4.7.  Treatment Compliance  ................................................................................................20  
3.5. Visit Schedule and Assessments  .................................................................................20  
3.5.1.  Study Procedures and Visit Schedule  .........................................................................20  
3.5.2.  Visit Schedule  .............................................................................................................23  
3.5.3.  Background Information .............................................................................................25  
3.5.4.  Efficacy Assessments  .................................................................................................25  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 7 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  3.5.5.  Safety Assessments  .....................................................................................................25  
3.5.5.1.  Local Tolerability Assessments  ..................................................................................25  
3.5.6.  Criteria for Changing the Application Site or Conditions  ..........................................27  
3.6. Adverse Events  ...........................................................................................................27  
3.6.1.  Method of Determining Adverse Events  ....................................................................27  
3.6.2.  Adverse Event Definitions  ..........................................................................................28  
3.6.2.1.  Adverse Events  ...........................................................................................................28  
3.6.2.2.  Serious Adverse Events  ..............................................................................................29  
3.6.2.3.  Severity of Adverse Events  ........................................................................................29  
3.6.2.4.  Relationship of Adverse Events to Study Treatments  ................................................29  
3.6.3.  Reporting Adverse Events  ..........................................................................................30  
3.6.4.  Adverse Event Follow -up ...........................................................................................30  
3.6.5.  Pregnancy reporting  ....................................................................................................31  
3.6.6.  Expected Adverse Events  ...........................................................................................31  
3.7. Instructions for Rapid Notification of Serious Adverse Events  .................................31  
3.7.1.  Contact person and number  ........................................................................................31  
3.7.2.  Reporting Responsibility  ............................................................................................31  
3.7.3.  Reporting procedures  ..................................................................................................32  
3.8. Appropriateness of Safety Measurements  ..................................................................32  
4. STATISTICAL METHODS  .......................................................................................33  
4.1. General Considerations for Data Analysis  .................................................................33  
4.2. Sample Size and Power Considerations  .....................................................................33  
4.3. Subject Populations  for Analysis  ................................................................................33  
4.3.1.  Background and Demographic Characteristics  ..........................................................33  
4.3.2.  Study Product/Visit Compliance  ................................................................................33  
4.4. Prior and Concomitant Medications  ...........................................................................33  
4.5. Efficacy Evaluation  ....................................................................................................34  
4.6. Safety  Evaluation  ........................................................................................................34  
4.6.1.  Cumulative Irritancy  ...................................................................................................34  
4.6.2.  Analysis of Dermal Sensitization Potential  ................................................................34  
4.6.3.  Adverse Events  ...........................................................................................................34  
4.7. Other topics  .................................................................................................................35  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 8 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  4.8. Interim analyses  ..........................................................................................................35  
4.9. Special Methods  ..........................................................................................................35  
5. ADMINISTRATIVE PROCE DURES  .......................................................................36  
5.1. Ethics and Good Clinical Practice  ..............................................................................36  
5.2. Institutional Review Board  .........................................................................................36  
5.3. Informed consent  ........................................................................................................36  
5.4. Declaration of Helsinki  ...............................................................................................37  
5.5. Changes in Planned Study Conduct  ............................................................................37  
5.5.1.  Protocol amendments  ..................................................................................................37  
5.5.2.  Other changes in study conduct  ..................................................................................37  
5.5.3.  Termination or suspension of study  ............................................................................38  
5.6. Data handling and record keeping  ..............................................................................38  
5.6.1.  Recording of data  ........................................................................................................38  
5.6.2.  Retention of documents  ..............................................................................................38  
5.7. Product handling and accountability  ..........................................................................38  
5.8. Quality control and quality assurance  .........................................................................39  
5.8.1.  Monitoring procedures  ................................................................................................39  
5.8.2.  Auditing procedures  ....................................................................................................39  
5.9. Confidentiality and publication policies  .....................................................................40  
5.9.1.  Disclosure and confidentiality  ....................................................................................40  
5.9.2.  Communication and publication of results  .................................................................40  
6. REFERENCES  ...........................................................................................................41  
 
LIST OF TABLES  
Table 1:  Fitzpatrick Skin Types  ................................................................................................21  
Table 2:  Visit Sche dule and Assessments  .................................................................................24  
Table 3:  Response Symbols and Numerical Equivalents  .........................................................25  
Table 4:  Effects on Superficial Layers of Skin .........................................................................26  
Table 5:  Other Notations  ...........................................................................................................26  
Table 6:  Relationship of AE to Study Drug ..............................................................................30  
 
 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 9 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  List of Abbreviation s  
 
ACD  Allergic Contact Dermatitis  
AE Adverse Event  
ANOVA  Analysis Of Variance  
CII Cumulative Irritancy Index  
CRF  Case Report Form  
DMP  Data Management Plan  
EBS Epidermolysis Bullosa  Simplex  
EOS  End Of Study  
FDA  Food And Drug Administration  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
IB Investigational Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IL Interleukin  
IP Investigational Product  
IRB Institutional Review Board  
MedDRA  Medical Dicti onary for Regulatory Activities  
MU Make -up Patch  
N9G  No 9th Grading  
NF National Formulary  
NP Not Patched  
NSAID  Non-steroidal anti -inflammatory drug   
OA Osteoarthritis  
OTC  Over -The-Counter  
PI Principal Investigator  
PMD  Primary Medical Doctor  
RIPT Repeated Insult Patch Test  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SOPs  Standard Operating Procedures  
TKL  TKL Research, Inc.  
UPT  Urine Pregnancy Test  
USP United States Pharmacopeia  
UV Ultraviolet  
 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 10 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  1. INTRODUCTION 
This study investi gates the sensitization  potential of CCP -020 (Diacerein 1%) Topical Ointment  
under standardized conditions com pared with an inert control (normal saline) .  Because CCP -020 
(Diacerein 1%) Topical Ointment is  formulated for topical use, it is necessary to  determine the 
potential of this  product to cause sensitization  after repeated topical application to the skin.   
The study will be conducted in compliance with Food and Drug Administration (FDA) 
regulations, the ethical principles of the Declaration of Helsi nki concerning medical research in 
humans (Recommendations Guiding Physicians in Biomedical Research Involving Human 
Subjects, Helsinki 1964 and amendments 2013), the Inte rnational Conference on Harmoniz ation 
(ICH) – Good Clinical Practice (GCP) Guidelines  as currently amended, and all applicable 
standard operating procedures (SOPs) of TKL Research, Inc . (TKL) . 
1.1. Background Information  
CCP-020 (previously developed as AC -203) is a topical ointment containing diacerein (4,5-
bis[acetyloxy] -9,10-dihydro- 9,10- dioxo -2-anthracene carboxylic acid; also known as diacetyl -
rhein), a highly purified anthraquinone derivative, and is being developed by Castle Creek 
Pharmaceuticals for the treatment of epidermolysis bullosa simplex (EB S).  The capsule 
formulation of diacere in, intended for oral use and systemic absorption, was initially approved 
for use in osteoarthritis (OA) in Fran ce in 1992 (as Artodar®, ART50®, or Zondar®).  Since then, 
it has received marketing authorization in over 30 countries in Europe, South America , and Asia.  
It is classified as a Symptomatic Slow -Acting Drug in OA.  Following oral administration of the 
capsule formulation, diacerein is rapidly metabolized to the deacetylated active metabolite, rhein.  
Similarly, diacerein in the topical formulatio n is hydrolyzed to rhein in the epidermis and the 
dermis following admin istration.  Diacerein and rhein  have been shown to inhibit the in vitro and 
in vivo production and activity of interleukin (IL) -1β and other proinflammatory cytokines.  It 
has a novel mode of action that differentiates it from non- steroidal anti- inflammatory drugs 
(NSAIDs) and other conventional forms of drug therapy.   
For the development of CCP -020, a total of 10 animal studies have been conducted with  CCP -
020 ointment 1%, including one skin penetration study, three acute dermal toxicity studies, one 
phototoxicity study, three pharmacokinetic studies, and two sub- chronic juvenile toxicity studies.  
CCP -020 was well -tolerated in these studies and n o untoward adverse effects  (AEs) were n oted.  
To date, two clinical studies of CCP -020 have been completed in patients with epidermolysis 
bullosa simplex (EBS) .  These include a Phase one pilot study in five patients and a Phase 2, 
multiple -site study in 17 patients in Europe.  The Phase 2 stud y demonstrated CCP -020 was 
well-tolerated and no treatment -related AEs were reported.  The Investigator’s Brochure should 
be consulted for summaries of the results of these studies.1  
This Phase 1 study will assess the irritation potential of  CCP-020 (Diac erein 1%) topical 
ointment.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 11 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  1.2. Rationale for the Study  
This study is intended to determine the contact sensitization (allergic) potential of topically 
applied CCP -020 (Diacerein 1%)  topical ointment treatment on normal skin in healthy 
volunteers.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 12 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  2. STUDY OBJ ECTIVES  
The primary objective of this study will be to deter mine the potential of CCP -020 (Diacerein 
1%) topical ointment to induce sensitization by repeated topical application to the healthy skin of 
humans under controlled conditions.   
In addition, saf ety will be assessed by evaluation of any AEs reported during the study.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 13 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  3. INVESTIGATIONAL PLAN  
3.1. Study Design  
This will be a randomized, single -center, controlled, evaluator -blinded, within -subject 
comparison study of the investigational product s (IPs)  (CCP -020 [Diacerein 1%] topical 
ointment  and vehicle) and negative irritant control under occlusive conditions in healthy 
volunteer subjects. All subjects will have fields designated  for the IP patches and the negative 
irritant control patch at 3 randomly assi gned, adjacent sites, for the purpose of determining 
sensitization potential.   
During the Induction P hase of the study, the IPs and negative irritant control  will be applied to 
adjacent sites on the infrascapular area of the back.  Evaluation of dermal re actions at the 
application sites will be assessed clinically using a visual scale that rates the degree of erythema, 
edema, and other signs of cutaneous irritation (see Section 3.5.5).   
Following the I nduction Phase, subjects will have a 10 to 14- day R est Period , after which they 
will enter the C hallenge Phase, which consists of one 48- hour patch application to a naïve  site on 
the opposite side of the back.  Observations based on the grading from Table 3 at the naïve site 
during C hallenge Phase and the pat terns of reactivity during the Induction Phase will provide a 
basis for an interpretation of contact sensitization (see  Section 3.5.5).   Notations on the 
appearance of the skin will be made using the scori ng system presented in Tables 4  and 5.   
If a cutan eous response observed in the C hallenge Phase indicates possible sensitization  (grade 3 
of higher from Table 3) , and/or at the discret ion of the Investigator, a Rechallenge will occur (see 
Section 3.5.1).  A narrative description of reactions in the C halle nge and Rechallenge P hases will 
be reported together with the opinion of the Investigator  as to whether such reactions are felt to 
be indicative of contact sensitization.  
A total of 10 patch applications will be made over a period of approximately 6- 8 week s. 
3.2. Discussion of Design  
Allergic contact dermatitis (ACD), also referred to as dermal sensitization, is a delayed -type 
hypersensitivity reaction induced by small reactive chemicals (haptens).2  It is a T -cell-mediated 
skin inflammatory systemic reaction, caused by repeated skin exposure to contact allergens.  
Erythema, edema, and occasionally papules and vesicles characterize the clinical appearance of 
this reaction.  The ACD inflammatory skin reaction occurs as a delayed response (24- 48 hours or 
longer) a fter contact with a sensitizing chemical.  
In pharmaceutical and cosmetic industries it is mandatory to identify chemicals that are potential 
ACD inducers before they become a part of a new product .2  Substances that come into contact 
with human skin need to be evaluated for their propensity to irritate and/or sensitize.  Once an 
appropriate pre -clinical safety evaluation has been performed, a reproducible, standardized, 
quantitative patch evaluation procedure must be used to demonstrate that a particular m aterial 
can be applied safely to human skin without significant risk of adverse reactions.3 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 14 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  Repeated insult patch test (RIPT) evaluation is a predictive patch study that can detect weak 
sensitizers that require multiple applications to induce a T -cell-medi ated (Type IV) immune 
response sufficient to cause an allergic reaction.  Irritant reactions may also be detected using 
this evaluation method, although this is not the primary purpose of this procedure.  
The human RIPT study design is based on the Modifie d Draize procedure, and is an accepted 
standard methodology used for assessment of skin sensitization.4, 5 
The IPs in the study will be  CCP -020 (Diacerein 1%) topical ointment and Vehicle.  The 
negative irritant control field will be 0.9% saline, 0.2 mL , applied topically under occlusive 
conditions. 
3.3. Study Population  
3.3.1. Subject Population 
A sufficient number of subjects will be  enrolled in order to provide 200 completed subjects 
evaluable for analysis; an individual subject will be allowed to participate in the  study one time 
only.   
A rationale for the choice of sample size is provided in Section 4.2 of this protocol. 
3.3.2. Inclusion and Exclusion Criteria  
Inclusion Criteria  
A subject will be considered eligible for participation in the study if all of the followin g inclusion 
criteria are satisfied prior to randomization:  
1. Is a healthy male or female (to be confirmed by medical history);  
2. Is 18 years of age or older;  
3. In the case of a female of childbearing potential, is using two  acceptable form s of birth 
control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom 
with spermicide, diaphragm with spermicide, abstinence, partner’s vasectomy, tubal 
ligation). Abstinence or vasectomies are acceptable if the female subject agrees to 
implement two  of the other acceptable methods of birth control if her lifestyle/partner 
changes;  
4. In the case of a female of childbearing potential, has a negative urine pregnancy test 
(UPT) on Day 1 prior to randomization and are willing to submit to a UPT at the e nd of 
study (EOS);  
5. Is free of any systemic or dermatological disorder, which, in the opinion of the 
Investigator, will interfere with the study results or increase the risk of AEs; 
6. Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation wi ll allow 
discernment of erythema (see Table 1);  
7. Complete a medical screening procedure; and  
8. Read, understand, and sign an informed consent. 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 15 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  Exclusion criteria  
A subject who has any of the following will be excluded from the study:  
1. Has any visible skin dise ase at the application site which, in the opinion of the 
Investigator, will interfere with the evaluation of the test site reaction; 
2. Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, 
or systemic/topical antihistamin es 72 hours prior to and during the study;  
3. Is not willing to refrain from using systemic/topical anti -inflammatory  analgesics such as 
aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 
hours prior to and during the study (occasional use of acetaminophen will be permitted);  
4. Is using medication which, in the opinion of the Investigator, will interfere with the study 
results (e.g. anti -inflammatory medications, antipsychotics, anticonvulsants with potential 
pain relief effect s, immunomodulatory medications, and others);  
5. Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, 
ointments, lotions or similar products on the back during the study;  
6. Has psoriasis and/or active atopic dermatitis/eczema;  
7. Has a known sensitivity or allergy to constituents of the materials being evaluated  
including diacerein, mineral oil, petrolatum, cetyl alcohol, D&C Yellow # 10 and/or ethyl 
paraben ; 
8. Is a female who is pregnant, plan to become pregnant during the study, or is bre ast 
feeding a child;  
9. Has damaged skin in or around the test sites, including sunburn, excessively deep tans, 
uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other 
disfigurations of the test site; 
10. Has received treatment for any type of internal cancer within 5 years prior to study entry;  
11. Has a history of, or are currently being treated for skin cancer and/or hepatitis;  
12. Has a history of, or is currently being treated for , insulin dependent diabetes ; 
13. Has any condition that might compromise study results;  
14. Currently or expect to sunbathe or use t anning salons during the study;  
15. Is currently participating in any clinical testing;  
16. Has any known sensitivity to adhesives; and/or  
17. Has received any investigational drug(s) within 4 weeks prior to stud y ent ry. 
3.3.3. Interruption or Discontinuation of Treatment  
In accordance with legal requirements and ICH -GCP guidelines, every subject or his/her legal 
representative has the right to refuse further participation in the study at any time and without 
providing reasons (see also Section 5.3).  A subject's participation is to be terminated 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 16 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  immediately upon his/her request.  The Investigator should seek to obtain the reason and record 
this on the case report form (CRF).  
If at the time of refusal a study produc t has already been administered, the subject should be 
advised on follow -up safety investigations. If a subject withdraws from the study, all efforts will 
be made to complete a final evaluation if possible. Subjects discontinued for having experienced 
an AE will be followed until the AE is resolved, a reasonable explanation is provided for the 
event , or the subject is referred to his/her own primary medical doctor (PMD). The specific AE 
in question will be recorded on the appropriate  CRF.  
If a subject devel ops a serious adverse event (SAE), his/her termination from the study will be 
considered by the Investigator.  Similarly, if the subject develops conditions over the course of 
the study which would have excluded his/her entry in the study according to the safety -related 
medical exclusion criteria, he/she must be withdrawn immediately.    
The subject may be withdrawn from the study at any time at the discretion of the Investigator for 
medical reasons and/or due to non- adherence to the treatment scheme and ot her duties stipulated 
in the study protocol.  The reasons are to be documented on the CRF.  
Individual patches may be discontinued if a reaction of a grade of 3 or greater (see Section 3.5.5 
for examples of values using additive grades from Tables 3 and Tab le 4) occurs at any point 
during the study.  Further patch applications of that product on that individual subject will be 
terminated.   A “not patched” (NP) symbol and a score of 3 will be assigned for all subsequent 
days.  
If a reaction is observed in any  induction evaluation, a change in site location for the remaining 
applications in the Induction Phase will take place for that particular patch.  See Section 3.5.5 for 
interpretations of scores.   
In addition, the Sponsor retains the right to end the stud y at any time if the study cannot be 
carried out as agreed upon in the protocol.  In case of premature termination or suspension of the 
study, the Sponsor’s study manager will promptly inform the Investigator/institutions and 
regulatory authorities of the termination or suspension and the reason for that.  It is the 
responsibility of the Principal Investigator (PI) to notify the Institutional Review Board (IRB) in 
the case of premature termination/suspension.  
3.3.4. Withdrawals  
The following medical and other rea sons justify a premature termination (by subject of 
Investigator) of any of the study IPs.  
• Adverse Event/Serious Adverse Event  
• Death  
• Protocol Violation (e.g. non- compliance)  
• Investigator Judgment  
• Pregnancy  
• Lost to Follow -up  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 17 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  • Withdrawal by Subject    
• Study Terminated by Sponsor  
• Other  
If a subject withdraws from the study, all efforts will be made to complete a final evaluation, if 
possible.  Subjects discontinued for having experienced an AE  will be followed until the AE is 
resolved, a reasonable explan ation is provided for the event, or the subject is referred to his/her 
own primary medical doctor (PMD).  The specific AE in question will be recorded on the appropriate CRF. 
3.4. Treatments  
3.4.1. Investigational Product and Controls  
Investigational Product(s): 
CCP -020 Topical Ointment 
CCP -020 is a topical ointment, 1% (w/w).  All excipients used in the topical formulation meet 
United States Pharmacopeia (USP)/ National Formulary (NF) criteria and are commonly used in 
ointment formulations.  CCP -020 topical ointment is packaged in aluminum tubes, at 25 g/tube.  
CCP -020 t
opical ointment and ve hicle  should be stored at room temperature (15°C/59°F to 
30°C/86°F).  The  PI will be responsible for the suitable storage of the IPs in compliance with the 
storage instructions and must restrict access to the investigative personnel only.   

Castle Creek Pharmaceuticals, LLC  Confidential   Page 18 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  Lot numbers will be given in the clinical study report.  
Manufacturer :  
     
TWi Pharmaceuticals will be responsible for the manufacturing and filling into the primary 
package; aluminum tubes.  TW i Pharmaceuticals will be responsible to package and distribute to 
TKL .  CCP will be responsible for final release of the product. TKL will be responsible for 
labeling the product upon site delivery. 
The IPs  will be dispensed via Eppendorf® Combitips onto separate occlusive patches at 
approximately 0.2 mL per patch applied 3 times weekly for 3 weeks (9 applications) during the 
Induction Phase, and one time at Challenge (10 times in total).  
Control 
A commercially available solution of 0.9% saline for topical administration (e.g., from Medline 
Industries Inc. (RDI30296)), applied 3 times weekly for 3 week s (9 applications) during the 
Induction Phase, and one time at Challenge (10 times in total). 
Eppendorf® Combitips will be used to apply 0.2 mL of the saline solution  to its designated 
occlusive patch . 
3.4.2. Description of Investigational Products  
The I Ps (CCP -020 [Diacerein 1%] topical ointment and vehicle)  will be supplied in aluminum 
tubes for the clinical study. CCP -020 (Diacerein 1%) topical ointment and vehicle were 
manufactured and packaged in accordance with good manufacturing practice (GMP).   
3.4.3. Descripti on of Patch Conditions  
CCP -020 (Diacerein 1%)  topical ointment, vehicle, and negative irritant control will be evaluated 
under occlusive patch conditions by means of application to a 2 x 2 cm Webril® pad.  The 
patches will be secured with nonporous Blende rm tape and hypoallergenic paper tape as needed.  
3.4.4. Packaging/Labeling  
The study medication tube label will show at least the following:  
• Protocol number 
• Storage conditions  
• Instructions for use 
• Expiration date 
• Sponsor information 
• Investigational drug warning 
• Space to enter lot number. 
A full product description can be found in the Investigator’s Brochure (IB).1 

Castle Creek Pharmaceuticals, LLC  Confidential   Page 19 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  All study IPs should be stored at room temperature (15°C/59°F to 30°C/86°F).  
3.4.5. Assignment to Treatment  
3.4.5.1. Randomization  
Each subject who signs an informed consent form (ICF) will be assigned a screening number.  If 
the subject meets all of the inclusion and none of the exclusion criteria, and successfully 
completes the screening procedures, they will be enrolled in the study.  Upon enrollment, each 
subject will be assigned a unique subject number and receive a randomization code, indicating 
application placement of the study materials.  Each subject in this study will serve as his or her 
own control.  All subjects will receive the IPs and control products at  adjacent application sites.   
The IPs ( CCP -020 [Diacerein 1%] topical ointment  and vehicle) and study control  (saline) will 
be assigned in a randomized seq uence to test Sites 1 through 3 using a set of independent 3- by-3 
Latin squares.  The same study mat erial will be applied to the same test site throughout the study.   
3.4.5.2. Blinding  
The treatments (IPs and control) will not be blinded to investigative personnel involved in the 
preparation/application and removal of treatments.   
Investigative personnel who ar e involved in the preparation/application and removal of the 
treatments will not perform the evaluation of skin responses.  Investigative personnel who are 
involved in the preparation/application and removal of the treatments will be unblinded.  The 
traine d evaluator who wi ll be evaluating skin responses  will be blinded to IPs and control and the 
treatment allocation; however, because of the demarcations/skin coloration remaining on the skin 
following patch removal, complete blinding of the evaluators cannot be completely assured.  
Investigative personnel, including the Investigator and trained evaluator involved in the 
evaluation of responses, will remain blinded during the course of the study until Database Lock 
and finalization of the Statistical Analysis Plan (SAP).  
In the event of an emergency, if possible, the Investigator or designee will contact the Sponsor 
with notification of the intent to unblind the treatment codes prior to the actual unblinding.  If it 
is not possible to notify the Sponsor prior t o the unblinding, the Investigator or designee will 
contact the Sponsor immediately following the unblinding procedure and follow with a written 
notification to document the exact manner in which the code was broken and the justification for 
the unblinding . The Investigator will communicate the treatment identification to only the 
investigative personnel who require the information to manage the emergency.  Unblinding will 
happen on site at TKL.  
3.4.6. Prior and Concomitant Therapy  
All medications, including over  the counter (OTC) drugs and vitamins, taken within 28 days 
prior to the start of the study will be recorded at Screening.  Thereafter, a record of all 
medications taken during the course of the study will be made.  Information regarding the total 
daily dose, route of administration, start and discontinuation dates, and indication are to be 
captured on the subject’s CRF.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 20 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  The following prohibitions will apply for the duration of the study:  
• There will be no use of systemic/topical anti -inflammatory  analgesi cs which in the 
opinion of the investigative personnel will interfere with the study results, including 
anti-inflammatory medications such as aspirin (81 mg aspirin will be allowed at the 
discretion of the Investigator), Aleve, Motrin, Advil, or Nuprin for  72 hours prior to 
and during the study (occasional use of acetaminophen will be permitted);  
• Use of sunbeds or sunlamps or deliberate exposure of the test sites to natural sunlight 
or to other sources of ultraviolet ( UV) light; 
• Participation in any other c linical study;  
• Soaking of test areas; and/or  
• Application of  any product to the test areas.  
The use of or change in the dose of any and all concomitant medication, either prescription or 
OTC, during the study will be recorded.  The reason for use or change  of dose of a concomitant 
therapy may need to be reported as an AE.  Therapies (medication and non -medication therapies) 
not restricted by the protocol may be used.  Non -prohibited chronic therapies being used at 
Baseline may be continued.   
All topical or  systemic medication listed in the exclusion criteria are prohibited during this study.  
See the IB for information about possible drug- drug interactions.1 
3.4.7. Treatment Compliance  
All patches will be applied and removed by investigative personnel.  Whereas ba thing will be 
allowed (low tub bath/frontal showers), the patched areas are not to be soaked and are to be kept 
as dry as possible, per the instructions to be given to each subject.  Subjects will be instructed to 
contact the Investigator before starting a ny medication, including OTC remedies.  In the case of 
an emergency treatment, the Investigator must be informed as soon as possible.  A trained, 
experienced evaluator will assess study compliance.   
Records of patch applications and visit schedule complia nce will be recorded on the subjects’ 
CRFs.  
If individual patches become dislodged or are misplaced, such that continuous contact with the 
skin has been interrupted, then patching at that site must be discontinued for the remainder of the 
study and that pa tch site will be considered not complete. If all patches become dislodged, the 
subject will be discontinued from further participation in the study.   
3.5. Visit Schedule and Assessments  
3.5.1. Study Procedures and Visit Schedule  
Screening  
At Screening, the subjects  will receive any necessary written an d verbal information, and the 
informed consent  of each subject will be obtained.  Demographic data (including Fitzpatrick skin 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 21 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  type) will be recorded, a medical history will be taken, and previous and concomitant 
medic ations will be reviewed.  Eligibility will be determined by review of the 
inclusion/exclusion criteria.   
• Any written and verbal information 
• Informed consent  
• Demographics  
• Previous/concomitant medication  
• Review of inclusion and exclusion criteria  
• Medical hi story (including lifestyle and habits)  
• Examination  of application site area  
Table  1: Fitzpatrick Skin Types  
I Always burns easily, never tans  
II Always burns easily, tans minimally  
III Burns moderately, tans gradua lly  
IV Burns minimally, always tans well  
V Rarely burns, tans very well  
VI Never burn, deeply pigmented4,5 
Day 1 
Prior to randomization, women of childbearing potential will be administered a UPT.  If the 
subject fulfills all of the inclusion and none of the exclusion criteria, he/she will be allowed 
participation in the study.  A Baseline evaluation of the patch sites will be performed prior to 
application of the patches to ensure that no conditions, markings, or coloration of the skin will 
interfer e with interpretation of the study results. Subjects will receive a unique randomization 
number, which determines the application scheme of the study materials for that individual 
subject.  
A set of 3 patches will be prepared in accordance with the randomi zation scheme on either the 
left or right side of the infrascapular area of the subject’s back  during the Induction Phase and 
the opposite side of the infrascapular area of the subject’s back during the Challenge Phase .  A 
visual inspection of skin clarity  and the side of patch application will be recorded on the CRF to 
ensure consistent placement of the patches at subsequent visits.  A baseline evaluation of the 
patch sites will be performed immediately prior to application of the patches to ensure that no  
conditions, markings, or coloration of the skin will interfere with interpretation of the study 
results.  The distance between the patches will be approximately 1 cm.  The numbering of the test 
sites will remain the same throughout the study . A surgical ma rker will be used to draw lines to 
indicate the 3 site locations for compliance purposes.  All patches will be affixed to the test sites 
on the intact skin of the infrascapular area of the subject’s back by investigative personnel.  
CCP -020 (Diacerein 1%) t opical ointment  and vehicle will be applied  in the amount of 0.2 mL to 
a 2 cm x 2 cm Webril® patch pad via Eppendorf® Combitips  and then applied to the subject’s 
skin surface as soon as possible following product application.  The sterile 0.9%  saline (nega tive 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 22 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  irritant control) will be applied to  a 2 cm x 2  cm Webril® patch pad  via pipette and then applied 
to the subject’s skin surface .  All 3  products will be evaluated under occlusive patch conditions 
by means of application to a 2 cm x 2 cm Webril® pad.  The patches will be secured with 
hypoallerg enic tape as needed . 
Induction  
The Induction Phase consists of a series of 9 applications of the study material and subsequent 
evaluations of the application sites.  The subjects will return to the facility  3 time s per week for 3 
consecutive weeks at 48 – 72 (± 4) hour intervals  to have the patches removed  (i.e. Mondays, 
Wednesdays, and Fridays for 3 consecutive weeks) .  Using a tissue, the evaluator will remove 
any remaining excess study material to avoid transfer ence of materials between sites.  The sites 
will be evaluated using the scoring system detailed in Section 3.5.5.  Identical patches will then 
be applied to the same sites.  A new tube of CCP -020 (Diacerein 1%)  topical ointment and 
vehicle will be opened every 14 days due to qualified product suitability (see Section 3.5.2).   
Subjects who are absent once during the 3- week, 9 -patch Induction P hase will be instructed to 
keep the patches in place  and return to the facility on their next scheduled visit .  They  will be 
scheduled to receive a make- up (MU)  patch application at the last I nduction visit.  The MU 
patches will be removed 48 – 72 (±4) hours later and the sites will be graded.  If subjects fail to 
return for removal/evaluation of the MU patch, a no nint h grading (N9G) will be recorded.  
In cases where the subject misses the 9th evaluation in Induction Phase, the subject will be 
allowed to remove the patches by themselves in accordance with investigative  personnel 
instructions. A telephone log will be writ ten for any subjects that experience this situation to 
document the telephone conversation regarding the removal by subject. 
Subjects who miss the 9th evaluation, but have had 9 patch applications will be considered to 
have completed the Induction P hase.  
During Induction, t he actual patch test grade is  a combination of a numerical ( Table 3 ) and letter 
(Table 4 ) grade consistent with the definitions given in the grading scales. A grade of 3 or higher 
to a specific study material  (see Section 3.5.5 for interp retation of symbols) observed at the first 
or second reading of the Induction P hase would indicate the subject is  pre-sensitized, and 
application of the product (s) in question would be discontinued.  If these reactions are observed 
after the first or secon d reading of the Induction Phase , this would necessitate a change in patch 
location to a naïve site.  A second site change to the specific study material would potentially 
require a patch condition change to semi -occlusive conditions for the remaining appl ications in 
the Induction Phase  (see Section 3.5.6).  
Rest Period  
During the Rest Period of approximately 10- 14 days, subjects will not receive any application of 
study materials.  
Challenge  
At the C hallenge  Phase, subjects who have completed the Induction P hase and the R est P eriod 
will hav e identical patches applied to naïve sites.  Patches will remain on the naïve  sites for 48  
(±1) hour  to be evaluated at  30 (+ 10)  minutes and 24 (± 1), 48 (± 1), and 72 (± 4) hours 
following patch removal (e .g., apply pa tch on Monday, remove patch on Wednesday, evaluate 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 23 
Clinical Study Protocol CCP -102-103    Protocol  DS106217   
Date 23-October -2017   Amendment  1 
 
Property of Castle Creek Pharmaceuticals, LLC     Clinical Study Protocol  test sites on Wednesday, Thursday, Friday, and Saturday), using the procedures described above 
for the Induction P hase.   A possible follow -up reading may be conducted at 96 (± 4) hours for 
subjects with a score of 3 or higher at the 72 (± 4) hour time point.   
Concomitant medications and AEs will be reviewed and recorded at the time of evaluation.  
To be considered a completed case, a subject must have 9 applications of the study material and 
no fewer than 8 subsequent readings during Induction Phase and one  application followed by 4 
subsequent readings during  the C hallenge Phase.  Only completed cases will be used to assess 
sensitization.  
Rechallenge  
A subject will be r echallenged to a specific study materi al if, in the opinion of the Investigator, 
any sign suggestive of contact sensitization (definite erythema with papules and/or edema) is 
observed at any of the 4 Challenge evaluations or at the Investigator’s discretion for that study 
material.  
Rechallenge patches will be applied at least 2 weeks after the end of the Challenge Phase.  The 
study material will be applied to naïve sites on the back, in a manner similar to that used in the 
Challenge P hase.  Rechallenge patches will remain in place for 48  (± 1) hour  and patch sites will 
be evaluated 3 0 (+ 10)  minutes  and 24 (± 1), 48 (± 1), and 72 (± 4)  hours after removal.  As an 
example, patches will be applied on Monday and removed on Wednesday; the test sites will be 
evaluated on Wednesday, Thursday, Friday, and the following Saturday . 
End of Study  
At the EOS,  all patches will be removed as described above, and the final evaluations of the test 
sites will be made.   
An EOS examination will be conducted and consist of the following:  
• Concomitant medication  
• AEs 
• UPT in females  of childbearing potential  
Concomitant medications and AEs will be reviewed and recorded during the whole study .  For a 
detailed listing of scheduled study  time points refer to the Visit Schedule and Assessments 
(Table 2 ). 
3.5.2. Visit Schedule  
A summary of the visit schedule and assessments is presented in Table 2 .  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 24 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Property of Castle Creek Pharmaceuticals, LLC      Clinical Study Protocol  
  
Table  2: Visit Schedule and Assessments  
 Screening  Induction  Rest Challenge  EOS  Rechallenge 
 Day -21 to -1 Weeks 1 -3 Weeks 4 -5 Week 6    
Infor med consent  X      
       
Demographics  X      
       
Inclusion/Exclusion  X      
       
Medical history  X      
       
UPT   Xa   X  
       
Randomization   Xa     
       
Study treatment applications and/or removals   X Xb X  X 
       
Evaluations   X Xc X  X 
       
Make -up applications (if applicable)   X     
       
Concomitant medications  X X X X X X 
       
Adverse events   X X X X X 
a: Day 1 only  
b: Day 1 of Week 4, removal/evaluation of last Induction patch.  
c: 48-72 (±4) hour evaluation of  MU patch (if applicable).  
Note:   The visit schedule may be revised if necessary.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 25 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Property of Castle Creek Pharm aceuticals, LLC    Clinical Study Protocol  
 3.5.3. Background Information  
Date of birth, gender, race, Fit zpatrick skin type (see Table 1 ), and a significant medical history  
of each subject will be recorded at Screening.  
3.5.4. Efficacy Assessments  
No efficacy will be assessed in this study.  
3.5.5. Safety Assessments  
3.5.5.1. Local Tolerability Assessments  
Assessment of the patch sites will be conducted by a trained evaluator  once at Baseline (Day 1), 
9 times during the Induction P hase, 4 times during the C hallenge  Phase and, if applicable, 4 
times during R echallenge.  The trained evaluator will assign a grade to each site ( Table 3).  
There will be a main evaluator for the study; a backup evaluator will also be assigned in the 
event that an emergency occurs and the main evaluator is unable to attend the study visit .  For 
the purpose of statistical analysis only, each grade will correspond to a score.  The following 
symbols and their respective numerical equivalents (see Table 3) will be used to express the 
response observed at the time of examination (see Table 4):  
Table  3: Response Symbols and Numerical Equivalents  
Grade  Score*    Definition  
0 0   No evidence of irritation  
1 1   Minimal erythema; barely perc eptible  
2 2   Definite erythema , readily visible; or minimal edema; or minimal papular response   
3 3   Erythema and papules  
4 3   Definite edema  
5 3   Erythema, edema, and papules  
6 3   Vesicular eruption  
7 3   Strong reaction spreading beyond test s ite 
*Scores are utilized only during the statistical analysis process of the study. Grades will be conducted throughout the 
study by the trained evaluator.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 26 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Property of Castle Creek Pharm aceuticals, LLC    Clinical Study Protocol  
  
Table  4: Effects on Superficial Layers of Skin  
Grade  Scor e* Response  
A 0 Slight glazed appearance  
C 1 Marked glazing  
E 2 Glazing with peeling and cracking  
F 3 Glazing with fissures  
G 3 Film of dried serous exudate covering all or portion of the patch  site 
H 3 Small petechial erosions and/or scabs  
*Scores are utilized only during the statistical analysis process of the study. Grades will be conducted throughout the 
study by the trained evaluator.  
Other notations (see Table 5 ) may be made in place of a score to designate particular 
circumstances preventing the assignment of a score or in addition to a score to identify damage 
to the epidermis and/or spreading of a reaction beyond the patch site.   
The actual patch test grades are a combination of a numerical ( Table 3 ) and letter ( Table 4 ) 
grades consistent w ith the definitions given in the grading scales. However, in order to determine 
discontinuation of a patch site (grade > 3) and to perform statistical analyses, grades containing 
letter grades have to be converted to numerical equivalents. These are conver ted as follows: A=0, 
C=1, E=2 and F, G, and H =3. These equivalents are considered additive to any numerical score 
(e.g., 2C=2+1=3), in this case the patch site would be discontinued. 
Table  5: Other Notations  
Notatio n   Definition  
X   Subject absent  
B   Burning or stinging sensation  
PD   Patch dislodged  
NA   Patch not applied  
NP   No patch due to limiting irritation  
I   Itching  
D   Damage of the epidermis: oozing, crusting, and/or superficial erosions  
p   Papu lar response  
pv   Papulovesicular response  
S   Spreading of reaction beyond patch site (i.e., reaction where s tudy material did not come in  c ontact 
with skin)  
T Tape related reaction  
Details regarding the statistical analysis of the cumulative irritation scores are provided in 
Section 4.6. 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 27 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 3.5.6. Criteria for Changing the Application Site or Conditions  
A grade of 3 or higher to a study product  (using Table 3 and Table 4 ) observed at the first or 
second reading of the I nduction P hase would indicate the subjec t to be pre -sensitized, and 
application of the product in question would be discontinued. 
After the second reading of the Induction Phase, reactions graded 3 or higher (using Table 3 or 
Table 4) require that the investigational product be applied to a naïve site under occlusive 
conditions.  Such a change of application site may occur no more than twice during the Induction 
Phase for a particular product, after which applications of the product will be discontinued for 
that subject for the remainder of the s tudy.  Subjects requiring site changes due to irritancy in the 
Induction Phase will be considered evaluable for sensitization, provided that they receive a total 
of no fewer than 9 applications of the product.   
No more than 2 changes for a given product  will occur, whether the changes are to a new site 
under occlusive conditions (first move) or a new site under semi -occlusive conditions  (second 
move). 
Occlusive patch conditions include a Webril® cotton patch surrounded with Blenderm tape and 
covered with paper tape.  There is no air flow under the patch.  Semi -occlusive patch conditions 
include a Webril® cotton patch covered with paper tape, to allow air flow under the patch itself.  
The 3 -week period of continuous patch contact during the Induction P hase fr equently results in 
tape- related irritation that is exacerbated by warm weather, but which occurs among some 
individuals irrespective of the season.  Since adhesive tape is an integral part of the test article, 
tape- related irritation at the site will be documented as an application site reaction using the 
symbol “T” from Table 5 .  Severe tape- related irritation will require a change of application site.   
Mild and moderate tape related reactions will not require of a change of application site.  If all 
sites are experiencing tape reactions, the patch sites will be discontinued and a not patched (NP) 
symbol will be recorded for the remainder of the study.  The subject will be discontinued from 
the study.  An AE will be recorded in order to follow through to r esolution of the tape related 
reaction.  
3.6. Adverse Events  
3.6.1. Method of Determining Adverse Events  
Safety assessments will include recording AEs reported spontaneously by the subject or collected 
by the Investigator.  AEs will be recorded at each visit throughout the study on the appropriate 
CRF.  Every attempt should be made to describe the AE in terms of a diagnosis.  If a clear 
diagnosis has been made, individual signs and symptoms will not be recorded unless they 
represent atypical or extreme manifestations  of the diagnosis, in which case they should be 
reported as separate events.   
Subjects should be asked whether, since the time of the last observation or visit, they had any of 
the following:  
• Experience any changes in well -being;  
• Used any new medications ;  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 28 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 • Changed medication regimens (both prescription and OTC); and/or  
• Were admitted to a hospital or had any accidents.  
All questions should be of a general nature and should not suggest symptoms.   
When an AE is suspected, all relevant evaluations will be carried out and appropriate treatment 
provided.  Additional follow -up will be done as necessary ( Section 3.6.4) and recorded in the 
subject’s source documents, and the results will be provided to the Sponsor.   
For AE definitions and reporting requirements refer to Section 3.6.2 and Section 3.6.3.  
Note:  Any observed response which can be denoted using the irritation criteria summarized in 
Table 3  and Table 4 will not be considered an AE .  Likewise, any tape- related irritation will only  
be noted as an AE  when all patches are discontinued due to tape reaction around all sites  (see 
Section 3.6.6) . 
3.6.2. Adverse Event Definitions  
3.6.2.1. Adverse Events  
Information about all local and systemic AE s, whether volunteered by the subject, discovered by 
Investigator questioning, or detected through other means, will be collected and recorded on the 
AE CRF and followed as appropriate.   
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product (or cosmeti c product), which does not necessarily 
have a causal relationship with this treatment.  An AE can therefore, be any unfavorable and 
unintended sign, symptom, or disease temporally associated with the use of a medicinal 
investigational product, whether or not considered related to the medicinal investigational 
product.   
Adverse Events will be coded using the Medical Dictionary for Regulatory Activities  
(Med DRA).  
Medical conditions/diseases present before starting study treatment are considered AEs only if 
they worsen after starting study treatment (any procedures specified in the protocol).  Any AEs 
occurring before starting study treatment but after signing the ICF are recorded on the Medical 
History/Current Medical Conditions CRF.  
To the extent possible, each AE will also be described by:  
1. its duration (start and end dates),  
2. the severity grade (mild, moderate, severe)  
3. its relationship to the study drug,  
4. the action(s) taken, and  
5. as relevant, the outcome.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 29 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 Note:  Any observed response which can be denoted usi ng the irritation criteria summarized in 
Table 3 and Table 4 will not be considered an AE.  Likewise, any tape -related irritation will not 
be noted as an AE.  
3.6.2.2. Serious Adverse Events  
A “SAE” is any AE that:  
• Results in death;  
• Is life -threatening (Note: the term “life -threatening” refers to any AE that, as it 
occurs, puts the subject at immediate risk of death.  It does not refer to an AE that 
hypothetically might have caused death if it were more severe).  
• Results in hospitalization or prolongation of current hospitalization (not including 
hospitalization for a pre -existing condition that has not increased in severity or 
frequency from the subject’s underlying medical condition prior to entry into the 
study).  
• Is a congenital anomaly/birth defect in the offspring of a subject.  
• Is another serious (important medical events) event.  
• Results in persistent or significant disability/incapacity.  
(Note: Important medical events may not be immediately life -threatening or result in death or 
hospitalization but may be considered serious when, based on the appropriate medical judgment, 
they may jeopardize the subject or require medical or surgical intervention to prevent one of the 
outcomes listed above.  Examples of such medical events include allergic bronchospasm 
requiri ng intensive treatment in an emergency room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or development of drug dependency or drug abuse.)  
3.6.2.3. Severity of Adverse Events  
“Severity” of the AE refers to the extent to which an AE affects the subject’s daily activities and 
differs from “Serious,” which is a regulatory classification.   
The Investigator is to classify the severity of an AE according to the following definitions: 
• Mild:  The symptom has a negligible effec t or no impairing effect on the subject’s 
normal function.  
• Moderate:  The symptom impairs the subject’s normal function to some extent.  
• Severe:  The symptom has an obvious, significantly impairing effect on the subject’s 
normal function.  
3.6.2.4. Relationship of A dverse Events to Study Treatments  
The Investigator is to classify the drug relationship of an AE according to the definitions outlined 
in Table 6 .  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 30 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 Table  6: Relationship of AE to Study Drug  
Association  Definition  
Not related  (1) the existence of a clear alternative explanation (e.g., mechanical bleeding at surgical 
site) or (2) non -plausibility, e.g., the subject is struck by an automobile or cancer 
developing a few days after drug administration.  
  
Unlikely  There is no medical evidence to suggest that the AE may be related to study drug usage, 
or there is another more probable  medical explanation.  
  
Possible  There is medical evidence to suggest that there is a reasonable possibility that the AE may 
be related t o study drug usage. However, other medical explanations cannot be excluded 
as a possible cause.  
  
Probable  There is strong medical evidence to suggest that the AE is related to study drug usage.  
  
Definite  A clinical event, including laboratory test a bnormality (if applicable), in which there is no 
uncertainty in its relationship to test drug (e .g., positive Rechallenge).  
3.6.3. Reporting Adverse Events  
Adverse events that occur from first dose through completion of the last study visit should be 
reported.  All SAEs, regardless of causality, occurring from the time of informed consent until 30 
days following study completion OR until 30 days after the subject’s last application of study 
medication, whichever is longer, must be reported to TKL Clinical Safety within 24 hours of the 
knowledge of the occurrence (this refers to any adverse event that meets any of the 
aforementioned serious criteria). SAEs occurring after the 30 -day follow -up period AND 
considered related to study drug must also be reported to the Sponsor.  
Every attempt should be made to describe the AE in terms of a diagnosis.  If a clear diagnosis 
has been made, individual signs and symptoms will not be recorded unless they represent 
atypical or extreme manifestations of the diagnosis, in which c ase they should be reported as 
separate events.  If a clear diagnosis cannot be established, each sign and symptom must be 
recorded individually.  
Any SAEs occurring in a subject receiving study drug must be reported to the Sponsor within 24 
hours of the s ite being informed of the event, even if the event does not appear to be drug -
related.  The report must be made by sending a completed SAE Report form to the Sponsor.  Any 
pertinent follow -up information should be provided in a similar manner.  Contact inf ormation is 
provided in Section 3.7.1. 
3.6.4. Adverse Event Follow -up 
Any ongoing AE at the time of study completion or withdrawal will be followed until the AE is 
resolved or the subject is referred to his/her own PMD.  The Investigator  and the Sponsor will 
decide if longer follow -up is appropriate on a case -by-case basis.  Subjects who experience any 
clinically significant AE will remain under medical supervision until the Investigator or the 
Sponsor’s Medical Monitor deems the AE to be resolved, stabilized, or no longer serious enough 
to warrant follow -up.   
Castle Creek Pharmaceuticals, LLC  Confidential   Page 31 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 3.6.5. Pregnancy reporting  
Prior to study enrollment, females of childbearing potential must be advised of the importance of 
avoiding pregnancy during study participation and the potential risk factors for an unintentional 
pregnancy.  The signed Informed Consent Form must document this discussion.   
A UPT will be performed on all females of childbearing potential at Day 1 (day of first patch 
application) and EOS.  All women of childbearing potential will receive a UPT prior to the first 
study drug administration and the study drug must be withheld until the results of laboratory 
pregnancy testing are available.  If pregnancy is confirmed, the subject must not receive any study drug and must not be enrolled in the study.  
3.6.6. Expected Adverse Events  
Any observed response in the patch test area that can be denoted using the irritation criteria 
summarized in Table 3 and Table 4 will not be considered an AE.   
Tape related reactions will only be recorded as AEs when the sub ject is discontinued due to tape 
reaction around all sites.  When 1 or 2 sites are experiencing severe tape related reactions, the 
application site will be stopped and the subject will continue on the study.  This will be noted in 
the database as “T” as indicated in Table 5  and will be considered an expected AE.  When all 
application sites are experiencing tape reaction, the subject is discontinued and therefore be 
recorded as an AE.  The subject will be followed up through resolution. 
3.7. Instructions for Rapid Notification of Serious Adverse E vents  
3.7.1. Contact person and number  
Serious adverse events must be reported immediately (i .e., not later than 24 hours after first 
knowledge) by e -mail with the scanned TKL SAE report form to: 
 
 
   
3.7.2. R eporting Responsibility  
Any death, SAE, pregnancy, (see Section 3.6), or unusual frequency of AEs , must be reported 
immediately (i.e., not later than 24 hours after first learning of its occurrence) to the Sponsor’s study manager by the Investigator, even if the event(s) appear to be unrelated to study treatment.  Follow-up information about a previously reported SAE or pregnancy must also be reported to 
the Sponsor within 24 hours of receiving it.  If the SAE or pregnancy has not been previously 
documented (i.e., is a new occurrence) and it is thought to be related to the investigational product (or therapy), the Sponsor may contact the Investigator to obtain further information.  If 
warranted, an investigator alert may be issued,  to inform all I nvestigators involved in any study 
with the same product (or therapy) that this SAE  or pregn ancy has been reported.   

Castle Creek Pharmaceuticals, LLC  Confidential   Page 32 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 The IRB should also be notified of SAEs or pregnancies and of any follow -up information in 
writing, as is practical, and depending on local regulations.   
3.7.3. Reporting procedures  
For each SAE, the Investigator  will complete a SAE Rep ort Form in English and assess the 
relationship of each SAE to study treatment.  The completed form(s) should be sent by e -mail to 
the S ponsor within 24 hours of first knowledge of the SAE (as outlined in Section 3.7.1 and 
Section 3.7.2).  The initial SAE should be reported immediately, even if only preliminary 
information is available .  Follow -up information should be sent by the same Investigator , 
restating the date of the original report.  Either a new SAE f orm is sent (stating that it is a follow -
up), or the original one is resent (with the new information highlighted and a new date provided).  
The follow -up should describe whether the event has resolved or continues, if and how it was 
treated, whether the blind was broken or not, and whether the patient  continued or discontinued 
study participation.  The form confirmation will be retained.  
Pregnancy follow -up (as outlined in Section 3.6.5) should be reported to the IRB within 24 hours 
of first knowledge on a Pregnancy Report Form.  Follow up will describ e the outcome of the 
pregnancy, including any voluntary or spontaneous termination, details of the birth, and the 
presence or absence of any congenital abnormalities or birth defects.   
3.8. Appropriateness of Safety Measurements  
The safety assessments in the study are standard safety measures in clinical trials.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 33 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 4. STATISTICAL METHODS  
4.1. General Considerations for Data Analysis  
The RIPT study design using 200 subjects is considered adequate to identify any significant 
safety hazard due to the potential of a topic ally administered dermatologic agent to induce 
allergenic sensitization.  Individual subje cts’ cutaneous responses after C hallenge Phase are 
classified as indicative of sensitization or not indicative of sensitization based on specific criteria 
defined in terms of an ordinal rating scale.  The occurrence in this study of even a single reaction 
indicative of sensitization is sufficient to suggest that the test product may have the potential to 
cause hypersensitivity.  
The statistical analyses described below will be supplemented by a comprehensive Statistical 
Analysis Plan (SAP) which will be finalized before the database is locked.  Any changes to the 
statistical plans will be described and justified in the final report.  
All statistical processing will be per formed using the SAS® system (version 9.2 or higher).  No 
interim or subgroup analyses are planned.  
4.2. Sample Size and Power C onsiderations  
The sample size of 200 evaluable subjects conforms to industry and regulatory standards for 
determinat ion of dermal sensitization potential.  In the absence of any sensitization reactions, a 
95% upper confidence bound on the population rate of sensitization would be 1.5%.  
4.3. Subject Populations for A nalysis 
All subjects who receive treatment will be evaluable for AEs.  The evaluation of sensitization 
will be based on all subjects who complete the C hallenge P hase of the study.  The analysis of 
cumulative irritancy will be based on  all subjects who complete the Induction P hase of the study.  
4.3.1. Background and Demographic C haracteri stics 
Descriptive statistics will be used to summarize demographic characteristics (age, gender,  
Fitzpatrick skin type, and race) and background characteristics for the randomized subject 
population.  Past/coexistent medical history information for all ran domized subjects will be 
presented in a by -subject listing.  
4.3.2. Study Product/Visit C ompliance  
Descriptive statistics will be used to summarize study product compliance for the randomized 
subject population. 
4.4. Prior and C oncom itant M edications  
Prior and concomit ant medication information for all randomized subjects will be presented in a 
by-subject listing.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 34 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 4.5. Efficacy Evaluation  
This section is not applicable to this study.  
4.6. Safety E valuation  
4.6.1. Cumulative I rritancy  
Cumulative irritancy during Induction will be quantif ied by means of the cumulative irritancy 
index (CII), defined as the mean of the total cumulative irritation scores received during the 
Induction Phase (9 readings).  The total cumulative irritation score for each subject and product 
will be calculated by summing each individual's scores on each of the 9 evaluation days in the 
Induction Phase.  Response grades will be assigned numerical scores according to Table 3 and 
Table 4.   Once the maximum score (combined score from Table 3 and Table 4) or a 3 or grea ter 
is achieved, the remaining scores of 3 will be carried forward through all subsequent readings.   
No data imputations are to be made for discontinued subjects or missed evaluations.   
The CII will be tested pairwise for product differences using Fisher ’s protected least significant 
differences in the context of the 2 -way analysis of variance (ANOVA) including main effects of 
subject and product, without interaction.  Pairwise differences will be tested for all products at 
the 5% level.  Mean cumulative irritation scores will also be presented for each patch in a listing.  
4.6.2. Analysis of Dermal Sensitization Potential  
The determination of dermal sensitization potential will be based on specific scoring criteria  
(Table 3)  derived from observations in the C hallenge P hase of the study and confirmed in the 
Rechallenge P hase, if necessary.  
Criteria specified in Section 3.5.5 may cause the continuation of a subject into the Rechallenge 
Phase of the study.  The recurrence of a cutaneous response of 3 or greater from Table 3 at 
Rechallenge equivalent to or mor e severe than that observed at C hallenge will be considered 
indicative of a sensitization reaction.  The observation of such a response in even a single subject 
suggests that the test product may have the potentia l to cause hypersensitivity.  
A narrative description of reactions in the C hallenge and Rechallenge P hases will be provided 
together with the opinion of the Investigator  as to whether such reactions are felt to be indicative 
of contact sensitization.  
4.6.3. Advers e Events  
Adverse events will be summarized as an overall incidence of at least one event, incidence 
within body systems only, incidence by body system and preferred term, and by highest severity .  
Each subject will contribute only once (e .g., the first oc currence) to each of the rates, regardless 
of the number of occurrences (events) the subject experiences.   
Treatment -emergent AEs will be summarized and tabulated by the system organ class and 
preferred term, by severity (mild, moderate, severe) and by re lationship to study product ( Not 
related, Unlikely, Possible, Probable, Definite )   
Castle Creek Pharmaceuticals, LLC  Confidential   Page 35 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 Treatment -emergent will be defined as any AE with an onset date on or after the first study 
product administration date.  Any event with a missing onset date will be includ ed as a 
treatment -emergent AE.  
Deaths and SAEs  will be listed by subject.  
4.7. Other topics  
There are no other topics being evaluated . 
4.8. Interim analyses  
No interim analyses are anticipated.  
4.9. Special M ethods  
This section is not applicable for this protocol.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 36 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 5. ADMINI STRATIVE PROCEDURES  
5.1. Ethics and Good Clinical Practice  
This study must be carried out in compliance with the protocol and in accordance with TKL 
Research, Inc.’s SOPs .  These are designed to ensure adherence to Good Clinical Practices 
guidelines, as describ ed in:  
• ICH Harmoniz ed Tripartite Guidelines for Good Clinical Practice 1996.  Directive 
91/507/EEC, The Rules Governing Medicinal Products in the European Community.  
• US 21 Code of Federal Regulations dealing with clinical studies (including parts 50 
and 56 concerning informed consent  and IRB/IEC/EEC regulations).  
• Declaration of Helsinki, concerning medical research in humans (Recommendations 
Guiding Physicians in Biomedical Research Involving Human Subjects, Helsinki 
1964 and amendments).  
The PI  agrees, wh en signing the protocol, to adhere to the instructions and procedures described 
in it and thereby to adhere to the principles of GCP  that it conforms to.  
5.2. Institutional Review Board  
Before implementing this study, the protocol, the ICF and other information to subjects, must be 
reviewed by a properly constituted IRB.  A signed and dated statement that the protocol and 
informed consent  have been approved by the IRB must be given to Castle Creek 
Pharmaceuticals, LLC  before study initiation.  This committee mus t also approve any 
amendments to the protocol, other than administrative ones, and a signed and dated statement of 
approval must be sent to Castle Creek Pharmaceuticals, LLC  prior to initiation of the amendment 
procedures .  The name and occupation of the c hairman and the members of the IRB must also be 
supplied to Castle Creek Pharmaceuticals, LLC . 
5.3. Informed consent  
The I nvestigator must explain to each subject (or legally authorized representative) the nature of 
the study, its purpose, the procedures involved, the expected duration, the potential risks and 
benefits involved, and any discomfort it may entail.  Each subject must be informed that 
participation in the study is voluntary, that he/she may withdraw from the study at any time, and 
that withdrawal of  consent will not affect his/her subsequent medical treatment or relationship 
with the treating physician.  
This informed consent  should be given by means of a standard written statement, written in non-
technical language.  The subject should read and consi der the statement before signing and 
dating it, and he/she should be given a copy of the signed document.  No subject can enter the 
study before informed consent  has been obtained from him/her, or his/her legally authorized 
representative.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 37 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 The ICF is consi dered to be part of the protocol, and must be submitted by the PI  with it for IRB 
approval.  Any changes to the proposed ICF suggested by the PI  must be agreed to by Sponsor  
before submission to the IRB and a copy of the approved version must be provided t o Sponsor 
after IRB approval.  
5.4. Declaration of Helsinki  
The PI  must conduct the study in accordance with the laws and regulations of the country in 
which the study is conducted, as outlined in the Declaration of Helsinki.  
5.5. Changes in Planned Study Conduct  
5.5.1. Protocol amendments  
With the exception of changes in the visit schedule and/or administrative changes, any changes 
or additions to this clinical study protocol require a written protocol amendment that must be 
approved by Castle Creek Pharmaceuticals, LLC and the PI  before implementation.  
Amendments significantly affecting the safety of subjects, the scope of the investigation or the 
scientific quality of the study, require additional approval by the appropriate IRB.  A copy of the 
written approval of the I RB, which becomes part of the protocol, must be given to Castle Creek 
Pharmaceuticals, LLC.   Examples of amendments requiring such approval are:  
1. an increase in study product dosage or duration of product exposure of subjects, 
2. a significant change in the st udy design ( e.g., addition or deletion of a control group),  
3. an increase in the number of invasive procedures to whi ch subjects are exposed, and  
4. addition or deletion of a test procedure for safety monitoring. 
These requirements for approval should in no way  prevent any immediate action from being 
taken by the Investigator  or the S ponsor in the interests of preserving the safety of all subjects 
included in the study .  If an immediate change to the protocol is felt to be necessary by the 
Investigator  and is im plemented by him/her for safety reasons the study S ponsor  should be 
notified and the IRB should be informed within 10 working days.  
Amendments affecting only administrative aspects of the study do not require formal protocol 
amendments or IRB approval, but  the IRB must be kept informed of such administrative 
changes.  Examples of administrative changes not requiring formal protocol amendments and 
IRB approval that can be treated as administrative amendments include:  
1. changes in the staff used to monitor studies , and  
2. minor changes in the packaging or labeling of the study product.  
5.5.2. Other changes in study conduct  
Deviations from the planned study conduct are not permitted; any unforeseen changes in study 
conduct must be reported to the S ponsor and noted in the final clinical study report.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 38 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 5.5.3. Termination or suspension of study  
Both the S ponsor and the PI  reserve the right to terminate or suspend the study at any time.  If 
study termination is n ecessary, the procedures will be arranged on an individual study basis af ter 
review and consultation by both parties.  It is the responsibility of the PI  to notify the IR B of the 
termination/suspension and the reason(s).  In terminating the study, the S ponsor  and the PI  will 
ensure that adequate consideration is given to the pr otection of the subjects’ interests.   
5.6. Data handling and record keeping  
5.6.1. Recording of data 
Case report forms will be designed to identify each subject by subject entry number and, where 
appropriate, subject's initials, the product being evaluated, and the r esults observed.  All entries 
to the CRFs must be made as instructed by the study S ponsor  at study initiation.  Data on 
subjects collected on CRFs during the study will be documented in an anonymous fashion, and 
the subject will only be identified by the s ubject number, and by his/her initials, if also required.  
If, as an exception, it is necessary for safety or regulatory reasons to identify the subject, both the 
study S ponsor and the PI  are bound to keep this information confidential.   
The PI must sign the designated page(s) of the CRFs, thereby stating that he/she takes 
responsibility for the accuracy of the data in the entire case record book.  All records will be kept 
in conformance to applicable national laws and regulations.  
The original signed ICF will be attached to each subject’s file.  When the study treatment is 
completed, the ICF will be kept in the appropriate file folder; otherwise a note indicating where 
the records can be located will be made.   
5.6.2. Retention of documents  
Storage is maintained  for 5 years  or until the Sponsor advises to release the archives  at either the 
TKL facility at One Promenade Blvd. Suite 1101/1201, Fair Lawn, NJ 07410 in a secured room 
accessible only to TKL employees, or at an offsite location that provides a secure environment 
with burglar/fire alarm systems, camera detection, and controlled temperature and humidity.  
Originals or copies of the CRFs, source documents, correspondence, IRB documents, study 
reports, etc . will be available for the S ponsor's review on the pr emises of TKL or at a secure 
location off -site.  All database management activities can be found in the data management plan 
(DMP).   
5.7. Product handling and accountability  
All product supplies are to be used only for this clinical study and not for any other  purpose.  
Study product supplies must be kept in an appropriate, secure area ( e.g., locked cabinet) and 
stored according to the conditions specified on the product labels.   
The PI  or a designee must maintain a full record of the shipment and application  of study product 
in a product accountability ledger.  This log must be kept current and should contain the 
following information:  
• identification of the subject to whom the  study product was dispensed,  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 39 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 • date(s) of the  study product dispensed to the subject, and  
• initials of the study site representative(s) dispensing study product.  
The inventory must be available for inspection by the study monitor.  A product -inventory and 
storage -facility inspection will be conducted at appropriate time intervals throughout the clinical 
investigation, depending on enrollment and the length of the study.  Any discrepancy and/or 
deficiency must be  accounted for by the PI  or his/her designee.  
The PI  must not destroy any product labels, or any partly used or unused product supply .  At the 
conclusion of the study and, as appropriate, during the course of the study, all study product 
supplies, including partially used or empty containers, must be returned according to the 
designation of the S ponsor.  Any missing supplies will be indicated on the inventory; the original 
inventory list will be retained  in the PI ’s records for this clinical study.  
5.8. Quality control and quality assurance  
5.8.1. Monitoring procedures  
During the study, the S ponsor may visit the site regularly to check the completen ess of subject 
records, the accuracy of entries on the CRFs, the adherence to the protocol and to ICH -GCP 
guidelines, the progress of enrollment, and also to ensure that study product is being stored, 
dispensed and accounted for according to specifications .  Key investigative  personnel will be 
available to assist the field monitor during these visits.  
The data required by the protocol must be recorded on the appropriate CRFs.  The CRFs and any 
source documents will be available to the study monitor who will  perform a 100% data check 
(comparison of the data recorded in the CRF with those in the source documents).  The CRFs 
and source data will also be available for an audit by the S ponsor or the FDA at any time.  
The I nvestigator will give the monitor access to relevant clinical records, to confirm their 
consistency with the CRF entries.  No information in these records about the identity of the 
subjects will leave the study center.  Additional checks of the consistency of the source data with 
the CRFs are per formed according to the study -specific monitoring plan.  
5.8.2. Auditing procedures  
In addition to the routine monitoring procedures, a study center may be audited in depth for 
study quality assurance by  the Sponsor , an external auditor on behalf of the S ponsor, a nd/or by 
regulatory authorities.  This audit may include a review of all source documents, drug records, 
and original CRFs the study site used in this  study.  Patient confidentiality will be maintained at 
all times and consent for this will be obtained bef ore entry of the patient into the clinical study  
(see Section 5.3).  If an inspection is requested by a regulatory authority, the PI  must 
immediately inform the study S ponsor that this request has been made.  
Castle Creek Pharmaceuticals, LLC  Confidential   Page 40 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 5.9. Confidentiality and publication policies 
5.9.1. Disclos ure and confidentiality  
By signing the protocol, the PI  agrees to keep all information provided by the S ponsor in strict 
confidence and to request similar confidentiality from his/her staff and the IRB.  Study 
documents provided by the S ponsor (protocols, IBs, CRFs and other material) will be stored 
appropriately to ensure their confidentiality.  The information provided by the S ponsor to the PI  
may not be disclosed to others without direct written authorization from the S ponsor, except to 
the extent necess ary to obtain informed consent  from subjects who wish to participate in the 
study.   
5.9.2. Communication and p ublication of results  
Any formal presentation or publication of data from this study will be considered as a joint 
publication by the I nvestigator(s) an d appropriate S ponsor personnel.  Authorship will be 
determined by mutual agreement.   
Castle Creek Pharmaceuticals, LLC must receive copies of any intended communication in 
advance of publication (at least 15 working days for an abstract or oral presentat ion and 45 
working days for a journal submission).  The S ponsor  will review the communications for 
accuracy (thus avoiding potential discrepancies with submissions to health authorities), verify 
that confidential information is not being inadvertently divulged and provide any relevant 
supplementary information. 
Castle Creek Pharmaceuticals, LLC  Confidential   Page 41 
Clinical Study Protocol CCP -102-103    Protocol DS 106217   
Date 23-October -2017   Amended 1 
 
Proper ty of Castle Creek Pharmaceuticals, LLC    Clinical Study Protocol  
 6. REFERENCES  
1. Investigator ’s Brochure. CCP -020 (Diacerein 1%) Topical Ointment. Castle Creek 
Pharmaceuticals, LLC. Version Number 1.0. 04 November 2016.  
2. Aeby P, Wyss C, Beck H, Griem P, Scheffler H and Goebel C.  Characterization of the 
Sensitizing Potential of Chemicals by In Vitro Analysis of Dendritic Cell Activation and 
Skin Penetration.  J Invest Dermatol 2004. 122: 1154- 1164. 
3. Lanman, BM, EB Elvers, and CJ Howard.  “The Role of Human Patch Testing i n a 
Product Development Program.”  Joint Conference on Cosmetic Goods Association,  
Washington DC, April 21- 23, 1968. 
4. Jordan, WP.  24- , 48-, and 48/48- hour Patch Tests.  Contact Dermatitis 1980. 6: 151- 152. 
5. Marzulli FN and Maibach HI.  Test Methods for All ergic Contact Dermatitis in Humans.  
In Dermatotoxicology.  Editors Marzulli FN and Maibach HI.  Washington, DC: 
Taylor  and Frances; 1998:153- 159.   
6. Fitzpatrick TB. The validity and practicality of sun -reactive skin types I through VI. 
Arch.Dermatol.  1988;  124: 869- 871. 
7. Sachdeva S. Fitzpatrick skin typing: Applications in dermatology. Indian J Dermatol 
Venereol Leprol 2009;75:93- 6 
 
 
 
 